DAPCEL, Inc enters into licensing agreements with Thermo Fisher Scientific and Daresbury Proteins Ltd regarding its patented (US20180319854A1/ WO2017068142A1) technology for enhanced recombinant protein expression in mammalian cells. This technology relies on the novel vector for protein expression, and methods of using such vector for the expression of proteins in mammalian cell lines (such as e.g. HEK293 and CHO), resulting in superior protein expression levels compared to other systems currently available on the market. Combination of this technology with DAPCEL, Inc unique approach for gene redesign represents additional opportunities for the production of correctly folded and active proteins in mammalian cell systems.